Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 2, 2015, Pages 211-218

  Dudley, Jonathan ^a,b   Tseng, Li Hui ^a,c   Rooper, Lisa ^a   Harris, Marco ^a   Haley, Lisa ^a   Chen, Guoli ^a   Gocke, Christopher D ^a   Eshleman, James R ^a   Lin, Ming Tseh ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CODON; DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; RAS PROTEIN;

ADJUVANT THERAPY; ALLELE; CHEMISTRY; CODON; COLORECTAL NEOPLASMS; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY;

ALLELES; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOADJUVANT THERAPY; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 84921476538     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0649-OA     Document Type: Article

References (34)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201-1208.
3. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptortargeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19): 1308-1324.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-1765.
5. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
6. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379.
7. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
8. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453(5):417-431.
9. Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med. 2004;128(12):1372-1378.
10. Angulo B, García-García E, Martínez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12(3): 292-299.
11. Tol J, Dijkstra JR, Vink-Börger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. 2010;14(8):2122-2131.
12. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffinembedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12(1):35-42.
13. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740.
14. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-1123.
15. Ondrejka SL, Schaeffer DF, Jakubowski MA, Owen DA, Bronner MP. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol. 2011;35(9):1327-1330.
16. Boissiere-Michot F, Lopez-Crapez E, Frugier H, et al. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Mod Pathol. 2012;25(5):731-739.
17. Lin MT, Tseng LH, Kamiyama H, et al. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Biotechniques. 2010;48(3):211-218.
18. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of sanger sequencing, pyrosequencing, and melting curve analysis for detection of KRAS mutations J Mol Diagn. 2010;12(4):425-432.
19. Chen G, Olson MT, O'Neill A, et al. A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn. 2012;14(2):149-159.
20. Lin MT, Tseng LH, Rich RG, et al. D-PCR, a simple method to detect translocations and insertion/deletion mutations. J Mol Diagn. 2011;13(1):85-92.
21. Lin MT, Mosier SL, Thiess M, et al. Clinical validation of KRAS, BRAF and EGFR mutation detection using next generation sequencing. Am J Clin Pathol. 2014;141(6):856-866.
22. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16(4):196-203.
23. Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. Acta Gastroenterol Belg. 2010;73(4):497-503.
24. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
25. Bazan V, La Rocca G, Corsale S, et al. Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas. J Cell Physiol. 2005;202(2):503-509.
26. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol. 2008;3(11):1224-1235.
27. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25(4):548-555.
28. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008;21;8:142.
29. Kobunai T, Watanabe T, Yamamoto Y, Eshima K. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun. 2010;395(1):158-162.
30. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010;5:23.
31. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A. 2011;108(50):20166-20171.
32. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530-9535.
33. Viray H, Li K, Long TA, et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med. 2013;137(11):1545-1549.
34. Smits AJ, Kummer JA, de Bruin PC, et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol. 2014;27(2):168-174.